Technology Themes From ASCO 2026: What Stood Out Beyond the Headlines

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms.

From BPIQ’s lens, several technology themes stood out.

ADCs Stayed at the Center of Oncology

Antibody-drug conjugates remained one of the most active modalities across the meeting.

Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Therapeutics all presenting programs across cervical and urothelial cancers. Beyond Nectin-4, the meeting also featured B7-H4, c-Met, HER2, and TROP2-directed ADC programs from companies including AstraZeneca, AbbVie, BeOne Medicines, Gilead, and Daiichi Sankyo.

The key message was clear: ADCs are no longer a narrow class. They are becoming one of the broadest competitive platforms in solid tumors.

Bispecific Antibodies Kept Expanding

Bispecifics continued to move across hematology and solid tumors.

In blood cancers, programs targeting CD20, BCMA, and related immune pathways remained active through Regeneron, Johnson & Johnson, Pfizer, and others. In solid tumors, BioNTech’s PD-L1 x VEGF-A bispecific in first-line NSCLC and BeOne’s GPC3 x 4-1BB bispecific showed how the field is pushing beyond classic hematology use cases.

This was one of the strongest signs that bispecifics are becoming a broader oncology platform, not just a hematology story.

Cell and TCR-T Therapies Continued Pushing Into Solid Tumors

Solid tumors remain one of the hardest frontiers for cell therapy, but ASCO 2026 showed continued progress.

Immatics had multiple PRAME and MAGEA4/8-directed updates across ovarian cancer, melanoma, synovial sarcoma, and other solid tumors. Replimune presented RP2 data in advanced solid tumors, AstraZeneca reported NT-175 data in TP53 R175H-mutated cancers, and Legend Biotech showed DLL3-targeted CAR-T activity in SCLC.

The theme was not that solid tumor cell therapy is solved. The theme was that the field is still moving, with better target selection, engineered receptors, and more defined patient populations.

RAS Targeting Became a Main Stage Story

Revolution Medicines made RAS one of the biggest technology stories of ASCO 2026.

Daraxonrasib’s Phase 3 pancreatic cancer data showed a major survival benefit in one of the hardest solid tumors to treat. That result did more than move one asset forward. It helped validate the broader idea that RAS-driven cancers can be targeted more effectively than many expected.

For oncology technology, this was one of the most important signals of the meeting.

Radioligand Therapy Broadened Beyond Prostate Cancer

Radioligand therapy also continued to expand.

Novartis presented radioligand data in both prostate cancer and SSTR-positive extensive-stage small cell lung cancer. This suggests the modality is still moving beyond its strongest early foothold and into additional tumor types where target expression can support the approach.

Precision Oncology Kept Getting More Precise

Across the meeting, patient selection kept narrowing.

Examples included non-classical EGFR mutations, ALK resistance, ESR1, PIK3CA, FGFR2 rearrangements, BRAF V600E, KRAS G12C, HLA-restricted melanoma, PRAME-positive tumors, and biomarker-defined NSCLC subgroups involving STK11, KEAP1, and KRAS.

The direction is clear: oncology is moving from broad tumor labels toward smaller, molecularly defined treatment groups.

Bottom Line

ASCO 2026 showed an oncology field increasingly shaped by platforms, not single drugs.

ADCs, bispecifics, cell therapies, TCR-T therapies, radioligands, RAS inhibitors, and precision oncology strategies all had meaningful visibility across the meeting.

The biggest takeaway from BPIQ’s lens: the next wave of oncology competition will not be defined only by positive data. It will be defined by differentiation, target selection, biomarker strategy, and commercial positioning inside increasingly crowded technology classes.

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 6/4/26 MD